GSK Expects 2025 Turnover Growth Of 3%-5%, Core EPS Rise Of 6%-8%, And Core Operating Profit Growth Of 6%-8%
2025 Guidance
GSK provides its full-year guidance at constant exchange rates (CER).
- Turnover is expected to increase between 3 to 5 per cent
- Core operating profit is expected to increase between 6 to 8 per cent
- Core earnings per share is expected to increase between 6 to 8 per cent
This guidance is supported by the following turnover expectations for full-year 2025 at CER
- Specialty Medicines – expected increase of a low double-digit per cent in turnover
- Vaccines – expected decrease of a low single-digit per cent in turnover
- General Medicines – expected to be broadly stable for turnover
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。